Academy of Thoracic Oncology - Multidisciplinary update on diagnostic and treatment pathways

The ESTS is delighted to announce the upcoming ERS-ESTS-ESTRO-ESR Academy of thoracic oncology - Multidisciplinary update on diagnostic and treatment pathways, scheduled to take place from 21 to 23 October 2026 in Zurich, Switzerland.

This important event will bring together leading experts and practitioners in thoracic surgery and respiratory medicine to share the latest advances in lung cancer diagnosis, treatment, and research.

Dates: 21–23 October 2026

Location: Zurich, Switzerland 

Meeting Program: Click here

Register here: Register now

Taking place in Zürich, Switzerland on 21-23 October, 2026, this collaborative course unites thoracic oncology experts to share comprehensive insights across the lung cancer spectrum, covering everything from screening and rapid diagnosis to palliative care and complex resuscitation ethics.

What does the course offer?

Organised by ERS, with expert contributions from the European Society of Thoracic Surgeons (ESTS), European Society for Radiotherapy and Oncology (ESTRO) and European Society of Radiology (ESR), the course aims to:

Present the latest evidence and best practices in lung cancer screening, staging, diagnosis and treatment.

Explore recent advances in diagnostic and therapeutic approaches.

Review standards for palliative care and decision-making around resuscitation.

Examine approaches to biopsy, biomarker integration and outcome prediction.

Who can attend?

Clinicians with a special interest in thoracic oncology/general respiratory, thoracic surgeons, medical oncologists, radiation oncologists, radiologists, palliative care physicians, clinical nurse specialists, early career members interested in thoracic oncology.

Learning objectives

Evaluate the current landscape of thoracic oncology diagnostics across diverse health settings.

Assess emerging technologies to anticipate and integrate future clinical advancements.

Critically review factors influencing treatment decisions within multidisciplinary team settings.

Design personalised lung cancer treatment strategies to optimise patient outcomes.

---